Rubin Marc 4
4 · GALECTIN THERAPEUTICS INC · Filed Feb 25, 2019
Insider Transaction Report
Form 4
Rubin Marc
Director
Transactions
- Sale
Common Stock
2019-02-21$6.02/sh−43,326$261,026→ 13,581 total - Exercise/Conversion
Stock option (right to buy)
2019-02-22−859→ 33,065 totalExercise: $2.39Exp: 2026-12-15→ Common Stock (859 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-02-21−43,326→ 33,924 totalExercise: $2.39Exp: 2026-12-15→ Common Stock (43,326 underlying) - Sale
Common Stock
2019-02-21$6.00/sh−7,000$42,000→ 13,581 total - Exercise/Conversion
Common Stock
2019-02-21$2.39/sh+43,326$103,549→ 56,907 total - Sale
Common Stock
2019-02-22$6.02/sh−859$5,175→ 13,581 total - Exercise/Conversion
Common Stock
2019-02-22$2.39/sh+859$2,053→ 14,440 total
Footnotes (4)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2018.
- [F2]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.02. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]The options vested 100% on December 14, 2018.